World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
66069
World Ranking
6110
National Ranking
3268

Overview

Jerald P. Radich is affiliated with the Fred Hutchinson Cancer Research Center in the United States. Their work primarily contributes to the field of medicine, with a strong focus on hematology, genetics, molecular biology, public health, environmental and occupational health, and cancer research.

The scientist has extensively studied topics relating to leukemia and cancer genomics. Their research covers:

  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Cancer Genomics and Diagnostics
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Eosinophilic Disorders and Syndromes

Jerald P. Radich has contributed to multiple publications, frequently publishing in the following venues:

  • Blood
  • Haematologica
  • Leukemia
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Transplantation and Cellular Therapy

Their recent papers include:

  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data, 2022, Blood
  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia, 2020, Leukemia
  • Management of chronic myeloid leukemia in 2023 - common ground and common sense, 2023, Blood Cancer Journal
  • Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia, 2020, JAMA Oncology
  • European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia, 2023, Leukemia

Jerald P. Radich collaborates frequently with several co-authors:

  • Lan Beppu
  • Cecilia C.S. Yeung
  • Megan Othus
  • Harry P. Erba
  • Olga Sala-Torra

Best Publications

  • Massively parallel digital transcriptional profiling of single cells

    Grace X. Y. Zheng;Jessica M. Terry;Phillip Belgrader;Paul Ryvkin

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

    Peter A. McSweeney;Peter A. McSweeney;Peter A. McSweeney;Dietger Niederwieser;Dietger Niederwieser;Dietger Niederwieser;Judith A. Shizuru;Judith A. Shizuru;Judith A. Shizuru;Brenda M. Sandmaier;Brenda M. Sandmaier;Brenda M. Sandmaier

  • Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

    Tim P. Hughes;Jaspal Kaeda;Susan Branford;Zbigniew Rudzki

  • THE CASE FOR EARLY DETECTION

    Ruth Etzioni;Nicole Urban;Scott Ramsey;Martin McIntosh

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Andreas Hochhaus;Richard A. Larson;François Guilhot;Jerald P. Radich

  • The role of FLT3 in haematopoietic malignancies

    Derek L. Stirewalt;Jerald P. Radich

  • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

    Timothy P Hughes;Michael W Deininger;Andreas Hochhaus;Susan Branford

  • Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

    A. Hochhaus;S. G. O'Brien;F. Guilhot;B. J. Druker

  • Lin28 promotes transformation and is associated with advanced human malignancies

    Srinivas R Viswanathan;John T Powers;William Einhorn;Yujin Hoshida

  • International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib

    Michael Deininger;Stephen G O'Brien;François Guilhot;John M Goldman

  • Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia

    John A. Hansen;Theodore A. Gooley;Paul J. Martin;Frederick Appelbaum

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Gene expression changes associated with progression and response in chronic myeloid leukemia

    Jerald P. Radich;Hongyue Dai;Mao Mao;Vivian Oehler

  • Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

    Soheil Meshinchi;William G. Woods;Derek L. Stirewalt;David A. Sweetser

  • Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

    Timothy P. Hughes;Andreas Hochhaus;Susan Branford;Martin C. Müller

  • FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

    Derek L. Stirewalt;Kenneth J. Kopecky;Soheil Meshinchi;Frederick R. Appelbaum

Frequent Co-Authors

Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Giuseppe Saglio
Giuseppe Saglio University of Turin
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Jorge E. Cortes
Jorge E. Cortes Augusta University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Ted Gooley
Ted Gooley Fred Hutchinson Cancer Research Center
Brent L. Wood
Brent L. Wood University of Washington
Todd A. Alonzo
Todd A. Alonzo University of Southern California
Michael W. Deininger
Michael W. Deininger University of Utah

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical education in the USA doesn't have to be limited to traditional MD programs. Many prospective healthcare professionals find online nursing degrees to be flexible pathways that align with their career goals. For those looking to quickly advance their qualifications, considering the shortest online dnp program options can provide a fast track to a Doctor of Nursing Practice degree, opening doors to advanced clinical and leadership roles.

Additionally, those seeking less rigorous entry requirements might explore the shortest dnp program opportunities. These programs are ideal for experienced nurses aiming for doctoral-level credentials in a condensed timeframe. If you're just starting your nursing journey, online lpn programs offer an accessible first step into healthcare, often completed faster than traditional pathways.

For those interested in mental health, specialized options like an online pmhnp program can prepare you to become a Psychiatric Mental Health Nurse Practitioner with speed and flexibility. Each pathway has its unique benefits and challenges, so carefully consider your career ambitions, timeline, and required credentials before deciding.

Best Scientists Citing Jerald P. Radich

Trending Scientists